Adalvo, in collaboration with Wyntra announce a significant milestone with the first launch from Adalvo’s Women's Health portfolio in the UK, reinforcing their shared commitment to expanding access to high-quality treatments.
This launch addresses a condition (endometriosis) that affects millions of women worldwide, with an estimated 10% of women of reproductive age impacted—equivalent to approximately 190 million women and girls globally [WHO, 2023]. By bringing this treatment to market, Adalvo and Wyntra are taking an important step in improving care and broadening therapeutic choices for patients and healthcare professionals.
“This launch marks a crucial step in our mission to expand access to high-quality women’s health treatments,” said Anil Okay, CEO of Adalvo. “By leveraging our expertise and strong partnerships, we continue to deliver impactful solutions that address real medical needs.”
Rahul Garella, Co-Founder & CCO of Wyntra , added, “Bringing this treatment to the UK is just the beginning. Together with Adalvo, we are committed to building a strong portfolio that enhances patient care and makes a meaningful difference.”
Get in touch today to explore partnership opportunities and expand access to Adalvo and Wyntra’s growing Women's Health portfolio.
About Adalvo
Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 130 countries and over 140 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering the highest quality differentiated products and services to our partners.
With headquarters in Malta, the company has additional offices in more than 19 countries. At Adalvo, we know that our partners like to be bigger, better, and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customised to our partners, and designed to challenge the status quo: together, this helps our partners achieve their business goals.
We take pride in our ability to help our partners reach their goals – be those increasing revenues or pushing into new markets. While partners are a high priority, Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion for making a difference for partners.
The company’s purpose-driven culture is committed to improving the lives of patients around the world. Our dynamic leadership team brings significant experience and industry know-how to Adalvo, which has helped to establish the company as a reliable global partner.
About Wyntra
Wyntra is a pharmaceutical company dedicated to bringing innovative, high-value prescription medicines to the UK market. We specialize in commercialising complex and differentiated therapies that address unmet medical needs while ensuring cost-effective solutions for patients and healthcare professionals. Through strategic partnerships with leading European and global pharmaceutical companies, Wyntra provides deep market access capabilities and commercial execution excellence.